Fujian Haixi Pharmaceuticals Management

Management criteria checks 3/4

Fujian Haixi Pharmaceuticals' CEO is Xinshan Kang, appointed in Mar 2012, has a tenure of 13.58 years. total yearly compensation is CN¥1.31M, comprised of 71.5% salary and 28.5% bonuses, including company stock and options. directly owns 16.2% of the company’s shares, worth HK$1.44B. The average tenure of the management team and the board of directors is 4 years and 2.6 years respectively.

Key information

Xinshan Kang

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentage	71.49%
CEO tenure	13.6yrs
CEO ownership	16.2%
Management average tenure	4yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Xinshan Kang's remuneration changed compared to Fujian Haixi Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2024	CN¥1m	CN¥933k	CN¥136m
Dec 31 2023	CN¥1m	CN¥952k	CN¥117m
Dec 31 2022	CN¥1m	CN¥964k	CN¥69m

Compensation vs Market: Xinshan's total compensation ($USD183.81K) is below average for companies of similar size in the Hong Kong market ($USD437.17K).

Compensation vs Earnings: Xinshan's compensation has been consistent with company performance over the past year.

CEO

Xinshan Kang (54 yo)

13.6yrs

Tenure

CN¥1,305,000

Compensation

Dr. Xinshan Kang is Co-Founder of Fujian HXPharma Co. Ltd. in March 2012. He serves as Director at Fujian HXPharma Co., Ltd.since March 2012 and was re-designated as executive Director in December 2024 an...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xinshan Kang	Co-Founder	13.6yrs	CN¥1.31m	16.2% HK$ 1.4b
Yan Feng	Co-Founder	13.6yrs	CN¥246.00k	12.6% HK$ 1.1b
Guangming Chen	Chief Scientific Officer	3yrs	CN¥1.10m	no data
Shuyi Chen	Executive Director	less than a year	CN¥467.00k	no data
Junhuan Zhang	Finance Director & Joint Company Secretary	4yrs	no data	no data
Hiu Lam Chan	Joint Company Secretary	less than a year	no data	no data
Kai Hu	Assistant President & Deputy GM	13.4yrs	no data	no data

4.0yrs

Average Tenure

55yo

Average Age

Experienced Management: 2637's management team is considered experienced (4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xinshan Kang	Co-Founder	13.6yrs	CN¥1.31m	16.2% HK$ 1.4b
Yan Feng	Co-Founder	7.9yrs	CN¥246.00k	12.6% HK$ 1.1b
Guangming Chen	Chief Scientific Officer	2yrs	CN¥1.10m	no data
Shuyi Chen	Executive Director	3.3yrs	CN¥467.00k	no data
Jiang Wu	Supervisor	4.9yrs	no data	no data
Xinkun Wang	Non-Executive Director	1.6yrs	no data	no data
Dong Xu	Non-Executive Director	2.2yrs	no data	no data
Shan Shan wang	Independent Non-Executive Director	less than a year	CN¥10.00k	no data
Weimin Gong	Independent Non-Executive Director	3yrs	CN¥43.00k	no data
Meiting Pu	Independent Non-Executive Director	less than a year	CN¥10.00k	no data
Xia Chen	Employee Representative Chairwoman of the Supervisory Board	9.5yrs	no data	no data
Lixia Xu	Supervisor	1.6yrs	no data	no data

2.6yrs

Average Tenure

46.5yo

Average Age

Experienced Board: 2637's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/28 18:29
End of Day Share Price	2025/10/28 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fujian Haixi Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.